Abstract:Therapeutic Advances in Drug Safety, Volume 15, Issue , January-December 2024. Background:Drug-induced interstitial lung disease (DILD) is an increasingly common cause of morbidity and mortality. However, due to the lack of specificity, DILD detection remains an unsolved public health challenge.Objectives:For the first time, we aimed to examine DILD reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to identify demographic characteristics and top drugs associated with DILD at a group level (including age, sex, drug class, and country stratification) and individual drug level.Design:A retrospective analysis of the FAERS database was examined by disproportionality analysis.Methods:We reviewed the FAERS database from 2004 to 2021, using search terms 'interstitial lung disease' and sorting cases by generic drug name. The reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network were calculated as the measure of strength of association.Results:There were 32,821 DILD reports in the FAERS. After excluding reports without age, sex, or country data according to the specific measurement, the median age of patients was 68 (interquartile range: 59), 54.77% were male, and 46.00% of reports came from Japan. The top drug classes related to DILD in the FAERS were antineoplastic, followed by cardiovascular and antirheumatic agents, in varying order in different sexes. Fam-trastuzumab deruxtecan-nxki, ramucirumab, and eribulin were the top three drugs with the highest strength of association. We also found some drugs without DILD in the labels, such as amiodarone, temsirolimus, and ursodiol. There are significant differences in DILD reports in various countries. For example, the United States and France reported more cardiovascular agents, whereas Canada reported more antirheumatic agents.Conclusion:We found the top drugs and drug classes that were associated with DILD in the FAERS, which provides a real-world window for different ages, sexes, and countries to formulate precise pharmacovigilance policies.Plain language summaryA study on drug-induced interstitial lung diseaseIntroduction: The Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database is the largest public database for spontaneous reporting of adverse events, any undesirable experiences that occur while taking a medication. The FDA designed the FAERS database to allow them to track the safety of drugs once they are released on the market. This study aims to explore drug-induced interstitial lung disease (DILD) reporting trends, demographic characteristics, most commonly reported drugs, and high strength of association drugs using the FAERS database.Methods: We retrieved the term 'interstitial lung disease' to extract DILD reports in the FAERS database from 2004 to 2021. Then, we not only counted basic patient information, including age, gender, and reporting country, but also analyzed the drug class, the reporting frequency of drug, and the degree of relevance.Results: We identified a total of 32,821 DILD reports. DILD reports had a persistent increase from 2004 to 2021. The top three drug classes related to DILD in the FAERS were antineoplastic, cardiovascular and antirheumatic agents. The top three reported drugs associated with DILD were methotrexate, doxorubicin, and pembrolizumab. The top three drugs with the highest strength of association were fam-trastuzumab deruxtecan-nxki, ramucirumab, and eribulin. Various countries have significant differences in drugs related to DILD.Conclusion: By analyzing data from the FAERS database, we identified the top drugs, drug classes, and some unexpected drugs without DILD in the labels. Our findings provide additional insight into DILD to inform clinicians to enhance monitor related to drugs of potential importance.

Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease

Drug-induced interstitial lung disease: a narrative review of a clinical conundrum

Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity

Pharmacogenetics and interstitial lung disease

Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the context of Anti-Cancer Therapy: a Multidisciplinary Viewpoint by Portuguese Experts

Feasibility of Using 18F-FDG PET/CT Radiomics and Machine Learning to Detect Drug-Induced Interstitial Lung Disease

Incidence and prognostic factors in severe drug-induced interstitial lung disease caused by antineoplastic drug therapy in the real world

Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases

A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease

Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021

Drug-induced lung disease: a narrative review

Drug-induced Acute Lung Injury

Potential drug-drug interactions in outpatient lung cancer patients in a university hospital

Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society

HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review

Interstitial lung disease associated with ALK inhibitors and risk factors: an updated comparative pharmacovigilance analysis

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs

Drug-induced Acute Lung Injury: A Comprehensive Radiologic Review

Identifying potential drug targets for idiopathic pulmonary fibrosis: a mendelian randomization study based on the druggable genes

Germline Genetic Variations in Drug Action Pathways Predict Clinical Outcomes in Advanced Lung Cancer Treated with Platinum-Based Chemotherapy